The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), announced today a new license agreement aimed at helping to prevent hundreds of thousands of deaths annually from rotavirus diarrhea in children living in developing countries. An effective oral rotavirus vaccine--created by NIAID scientists in the mid- to late 1980s and developed further through a Cooperative Research and Development Agreement with an industry partner--has now been licensed by the NIH Office of Technology Transfer to BIOVIRx, Inc., of Minneapolis, MN. BIOVIRx, which is responsible for obtaining requisite marketing approvals for this product, plans global commercialization of the oral vaccine (RotaShield).
Rotaviruses are consistently shown to be the leading cause of severe diarrhea in infants and young children. Worldwide, the wheel-shaped viruses are estimated to cause more than 135 million episodes of diarrhea each year in infants and children younger than 5 years old, resulting in up to 592,000 deaths annually.
Rotaviruses are egalitarian viruses: they readily infect and cause illness in infants and young children in both developed and developing countries. The overall consequences of these illnesses, however, are quite different. Approximately 1,600 rotavirus-related deaths each day occur predominantly in the developing countries, notes Albert Z. Kapikian, M.D., who led the NIAID team that developed the vaccine and serves as head of the epidemiology section in the Institute's Laboratory of Infectious Diseases.
Symptoms of rotavirus infection develop quickly and in addition to diarrhea, may include vomiting, fever and dehydration. The resulting dehydration can be reversed through oral rehydration therapy or, in more serious cases, through hospitalization and intravenous fluids.
Although effective, these therapies are not readily available or used in many parts of the developing world. Children in developing Page: 1 2 Related medicine news :1
Contact: NIAID Press Office
NIH/National Institute of Allergy and Infectious Diseases
. NIAID initiates trial of experimental avian flu vaccine2
. NIAID seeks applicants to lead clinical trials units for revamped HIV/AIDS networks3
. NIAID begins enrolling volunteers for novel HIV vaccine study4
. NIAID-sponsored clinical trial aims to boost flu vaccine supply5
. NIAID seeks applicants to lead revamped HIV/AIDS clinical trials networks6
. NIAID launches influenza genome sequencing project7
. NIAID launches program to improve medical tools against emerging infectious diseases8
. NIAID forms network to tackle potentially fatal reaction to smallpox vaccine9
. Second NIAID SARS vaccine candidate helps mice fend off SARS10
. NIAID vaccine protects against SARS virus infection in mice11
. NIAID Ebola vaccine enters human trial